In HIV, Greater BMD Decline for Immediate Versus Delayed ART

This article originally appeared here.
Share this content:
In HIV, Greater BMD Decline for Immediate Versus Delayed ART
In HIV, Greater BMD Decline for Immediate Versus Delayed ART

FRIDAY, June 30, 2017 (HealthDay News) -- Immediate antiretroviral (ART) initiation at HIV diagnosis is associated with greater bone mineral density (BMD) declines compared with deferred initiation, according to a study published online June 26 in the Journal of Bone and Mineral Research.

Jennifer F. Hoy, M.B.B.S., from Monash University and the Alfred Hospital in Melbourne, Australia, and colleagues compared the effect of early ART (CD4 <500 cells/µL) with deferred ART on the change in BMD, measured annually at the lumbar spine and hip using dual energy X-ray absorptiometry (DXA). Baseline and follow-up DXA scans were available for 195 participants in the immediate group and 204 in the deferred group.

The researchers found that, compared with deferred ART, immediate ART correlated with significantly greater BMD declines at the hip (−2.5 versus −1.0 percent; difference, −1.5 percent) and spine (−1.9 versus −0.4 percent; difference, −1.6 percent), through 2.2 years mean follow-up. The greatest declines in BMD were seen in the first year of ART. Spine BMD stabilized in the immediate ART group after one year, while hip BMD declined progressively over two years. BMD changes were similar in the immediate and deferred groups after year one.

"All HIV treatment guidelines now recommend ART initiation at HIV diagnosis because of the reduced risk of serious clinical outcomes," the authors write. "Better understanding of the longer-term consequences of the observed reductions in BMD is needed."

Several pharmaceutical companies donated antiretroviral drugs.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »